Trimtabs Asset Management buys $1,545,267 stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Trimtabs Asset Management scooped up 1,616 additional shares in United Therapeutics Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 12,376 shares of United Therapeutics Corporation which is valued at $1,545,267.United Therapeutics Corporation makes up approximately 0.96% of Trimtabs Asset Management’s portfolio.

Other Hedge Funds, Including , Wright Investors Service Inc sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 2,180 shares of UTHR which is valued $272,195.Sumitomo Mitsui Asset Management Company Ltd boosted its stake in UTHR in the latest quarter, The investment management firm added 50 additional shares and now holds a total of 3,194 shares of United Therapeutics Corporation which is valued at $386,506. United Therapeutics Corporation makes up approx 0.01% of Sumitomo Mitsui Asset Management Company Ltd’s portfolio.Mu Investments Ltd. reduced its stake in UTHR by selling 700 shares or 39.77% in the most recent quarter. The Hedge Fund company now holds 1,060 shares of UTHR which is valued at $119,992. United Therapeutics Corporation makes up approx 0.08% of Mu Investments Ltd.’s portfolio.

United Therapeutics Corporation opened for trading at $125.29 and hit $126.48 on the upside on Thursday, eventually ending the session at $125.48, with a gain of 0.50% or 0.62 points. The heightened volatility saw the trading volume jump to 5,95,140 shares. Company has a market cap of $5,454 M.

On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.